Pneumocystis carinii remains a persistent cause of severe
pneumonia in immune compromised patients. Recent studies indicate that P. carinii is a fungal species possessing a
glucan-rich
cyst wall.
Pneumocandin antagonists of
beta-1,3-glucan synthesis rapidly suppress
infection in animal models of P. carinii
pneumonia. We, therefore, sought to define the molecular mechanisms of
beta-glucan cell wall assembly by P. carinii. Membrane extracts derived from freshly purified P. carinii incorporate
uridine 5'-diphosphoglucose into insoluble
carbohydrate, in a manner that was completely inhibited by the
pneumocandin L733-560, an antagonist of Gsc-1-type
beta-glucan synthetases. Using degenerative polymerase chain reaction and library screening, the P. carinii Gsc-1 catalytic subunit of
beta-1,3-glucan synthetase was cloned and characterized. P. carinii gsc1 exhibited homology to phylogenetically related fungal
beta-1,3-glucan synthetases, encoding a predicted 214-kDa
integral membrane protein with 12 transmembrane domain structure. Immunoprecipitation of P. carinii extracts, with a synthetic
peptide anti-Gsc-1 antibody, specifically yielded a
protein of 219.4 kDa, which was also capable of incorporating 5'-diphosphoglucose into insoluble
glucan carbohydrate. As opposed to other fungi, the expression of gsc-1
mRNA is uniquely regulated over P. carinii's life cycle, having minimal expression in trophic forms, but substantial expression in the thick-walled cystic form of the organism. These results indicate that P. carinii contains a unique catalytic subunit of
beta-1,3-glucan synthetase utilized in
cyst wall formation. Because synthesis of
beta-1,3-glucan is absent in mammalian cells, inhibition of the P. carinii Gsc-1 represents an attractive molecular target for therapeutic exploitation.